Compile Data Set for Download or QSAR
Report error Found 152 Enz. Inhib. hit(s) with all data for entry = 7513
TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199025(BDBM199037 | BDBM199038 | US9221832, 89)
Affinity DataIC50: 2.20nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199025(BDBM199037 | BDBM199038 | US9221832, 89)
Affinity DataIC50: 3.20nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM198941(BDBM198943 | BDBM198942 | US9221832, 5)
Affinity DataIC50: 3.5nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199023(US9221832, 87)
Affinity DataIC50: 4.60nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM198970(BDBM199009 | US9221832, 34 | BDBM199010)
Affinity DataIC50: 4.70nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199064(US9221832, 128)
Affinity DataIC50: 5.60nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199046(US9221832, 110)
Affinity DataIC50: 6.70nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM198970(BDBM199009 | US9221832, 34 | BDBM199010)
Affinity DataIC50: 7.40nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199050(US9221832, 114)
Affinity DataIC50: 7.60nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199045(US9221832, 109)
Affinity DataIC50: 9nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199021(BDBM199022 | BDBM199029 | BDBM199028 | US9221832, ...)
Affinity DataIC50: 9nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM198970(BDBM199009 | US9221832, 34 | BDBM199010)
Affinity DataIC50: 9.90nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199021(BDBM199022 | BDBM199029 | BDBM199028 | US9221832, ...)
Affinity DataIC50: 11nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM198941(BDBM198943 | BDBM198942 | US9221832, 5)
Affinity DataIC50: 12nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199066(US9221832, 131)
Affinity DataIC50: 14nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199033(US9221832, 97)
Affinity DataIC50: 15nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199019(US9221832, 83)
Affinity DataIC50: 15nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199021(BDBM199022 | BDBM199029 | BDBM199028 | US9221832, ...)
Affinity DataIC50: 15nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM198941(BDBM198943 | BDBM198942 | US9221832, 5)
Affinity DataIC50: 16nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199039(US9221832, 103)
Affinity DataIC50: 16nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM198985(US9221832, 49)
Affinity DataIC50: 17nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199002(US9221832, 66)
Affinity DataIC50: 20nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199015(US9221832, 79)
Affinity DataIC50: 21nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199069(US9221832, 134)
Affinity DataIC50: 21nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199011(US9221832, 75 | BDBM199034 | BDBM199035)
Affinity DataIC50: 22nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM198968(US9221832, 32)
Affinity DataIC50: 23nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 23nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 24nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199049(US9221832, 113)
Affinity DataIC50: 28nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199011(US9221832, 75 | BDBM199034 | BDBM199035)
Affinity DataIC50: 29nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM198944(BDBM198965 | BDBM198964 | US9221832, 8)
Affinity DataIC50: 29nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199043(US9221832, 107)
Affinity DataIC50: 31nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM198937(US9221832, 1 | BDBM198940 | BDBM198939)
Affinity DataIC50: 33nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199021(BDBM199022 | BDBM199029 | BDBM199028 | US9221832, ...)
Affinity DataIC50: 33nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199072(US9221832, 137)
Affinity DataIC50: 37nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199065(US9221832, 146 | US9221832, 147 | US9221832, 130)
Affinity DataIC50: 40nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM198937(US9221832, 1 | BDBM198940 | BDBM198939)
Affinity DataIC50: 40nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199011(US9221832, 75 | BDBM199034 | BDBM199035)
Affinity DataIC50: 40nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 41nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM198937(US9221832, 1 | BDBM198940 | BDBM198939)
Affinity DataIC50: 42nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 42nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199068(US9221832, 133)
Affinity DataIC50: 43nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM198944(BDBM198965 | BDBM198964 | US9221832, 8)
Affinity DataIC50: 43nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 45nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199079(US9221832, 144)
Affinity DataIC50: 50nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 50nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199036(US9221832, 100)
Affinity DataIC50: 52nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 52nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199042(US9221832, 106)
Affinity DataIC50: 52nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM198975(US9221832, 39)
Affinity DataIC50: 54nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

Displayed 1 to 50 (of 152 total ) | Next | Last >>
Jump to: